A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 370 participants.

Also called NCT01051011

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 370 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01051011
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, Hong Kong SAR China, Malaysia, Philippines, South Korea, Taiwan, Thailand (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01051011. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy
Condition
Diabetes Mellitus Type 2
Intervention (Drug)
insulin glargine
Intervention (Drug)
metformin
Intervention (Drug)
taspoglutide
Intervention (Drug)
taspoglutide
Lead sponsor
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct01051011
Content hash
51490eadd5608452406d1a2bf5c0b577a76baf00d6cb9b29f1b295848c947fc3